The drub Monoclonal, which is used to treat neck, head, and colorectal cancer, is being studied for the treatment of Mesothelioma. In the most recent studies, which were conducted by a team of researchers in Japan, they found that the drug Monoclonal did inhibit the growth of Mesothelioma cells when used in baseline studies and in mice who were infected with Mesothelioma cells.
Mesothelioma is a fast acting and aggressive cancer that attacks the mesothelium tissue, generally around the lungs. However, other places that this cancer originates can be in the mesothelium surrounding the heart or the intestines. The disease is extremely resistant to most treatments for cancer, and is often times fatal. In most cases, it is linked to exposure to asbestos. As many countries around the globe continue to develop, the number of annually diagnosed Mesothelioma cases continues to rise. In the United States alone, there are about 2500 new cases diagnosed each year. In most instances, people newly diagnosed with Mesothelioma live between 12 and 18 months from the date of diagnosis.
The new treatment using the antibody Monoclonal works by creating an antibody-dependent cellular cytotoxicity (ADCC). This fights against the increased production of cancerous cells caused by the epidermal growth factor receptor (EGFR). Researchers recently developed a new drug, cetuximab, which has been derived from the human/mouse hybrid cells. During research studies, this drug was effective because it inhibited the growth of cells by decreasing EGFR using ADCC.
According to the International Journal of Oncology, the drug cetuximab inhibited tumor growth in the thoracic region significantly and increased the lifespan of the mice who were infected with Mesothelioma and given the drug as treatment. This study has lead to a phase II multicenter study, being conducted in Belgium. In this study, the drug cetuximab is being used as first-line treatment in Mesothelioma patients who have undergone radical surgery to have the cancer removed, yet it has returned. In this particular study, cetuximab is being combined with a minimum of one chemotherapy drug. The drug combinations could include cetuximab with carboplatin, cisplatin, and/or pemetrexed.
As research continues and scientists become more and more knowledgeable about potentially effective treatment options for Mesothelioma, the chances of a better quality of life and increased lifespan after diagnosis continue to grow. Treatment options for Mesothelioma continue to increase. However, many of them are still in the research phase. Proper treatment of Mesothelioma depends on the stage of the cancer at the time of diagnosis and the condition of the body to be able to handle and endure the chosen treatment. Options for treatment are typically determined by the physician, specialists, and the patient.